SCHEMBL15083131

SCHEMBL15083131

CC(C)(C)OC(=O)N[C@@H](CCC(=O)NCC(=O)OCc1ccccc1)C(=O)OCc1ccccc1

nearest known ligand 0.51

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
KLK7 P49862 3/20 0.51
KLK5 Q9Y337 2/20 0.51
CTSS P25774 4/20 0.50
PPARA Q07869 3/20 0.50
SYK P43405 1/20 0.50
BCHE P06276 1/20 0.50
ACHE P22303 1/20 0.50
CTSK P43235 4/20 0.49
ACE P12821 1/20 0.49
CTSL P07711 1/20 0.48
CTSB P07858 1/20 0.48
PPARG P37231 2/20 0.47
MAPT P10636 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23156977 1.00 KLK7 (0.51) KLK7KLK5CTSSPPARASYK
SCHEMBL23056261 0.94 KLK7 (0.51) KLK7KLK5CTSSPPARASYK
SCHEMBL16288805 0.94 PPARA (0.55) KLK7KLK5CTSSPPARASYK
SCHEMBL14864738 0.93 CTSS (0.56) KLK7KLK5CTSSPPARASYK
SCHEMBL10284237 0.93 CTSS (0.56) KLK7KLK5CTSSPPARASYK
SCHEMBL24945913 0.90 ACE (0.55) KLK7KLK5CTSSPPARASYK
SCHEMBL24945920 0.90 ACE (0.55) KLK7KLK5CTSSPPARASYK
SCHEMBL952328 0.90 CTSK (0.56) KLK7KLK5CTSSPPARASYK
SCHEMBL952329 0.90 CTSK (0.56) KLK7KLK5CTSSPPARASYK
SCHEMBL9403798 0.90 BCHE (0.50) CTSSBCHEACHECTSKCTSL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12415835-B2 Peptide-compound cyclization method CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2025-09-16 US disclosed
US-11891457-B2 Peptide-compound cyclization method CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2024-02-06 US disclosed
EP-3974563-A1 CYCLIC PEPTIDES Chugai Seiyaku Kabushiki Kaisha (JP) 2022-03-30 EP disclosed
US-20210061860-A1 PEPTIDE-COMPOUND CYCLIZATION METHOD CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2021-03-04 US disclosed
US-20160311858-A1 PEPTIDE-COMPOUND CYCLIZATION METHOD CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2016-10-27 US disclosed
US-9409952-B2 Peptide-compound cyclization method CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2016-08-09 US disclosed
US-9409952-B2 Peptide-compound cyclization method CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2016-08-09 US disclosed
US-20150080549-A1 PEPTIDE-COMPOUND CYCLIZATION METHOD CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2015-03-19 US disclosed
US-20150080549-A1 PEPTIDE-COMPOUND CYCLIZATION METHOD CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2015-03-19 US disclosed
EP-2813512-A1 PEPTIDE-COMPOUND CYCLIZATION METHOD Chugai Seiyaku Kabushiki Kaisha (JP) 2014-12-17 EP disclosed
WO-2013100132-A1 PEPTIDE-COMPOUND CYCLIZATION METHOD 中外製薬株式会社 (JP) 2013-07-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11891457-B2 Peptide-compound cyclization method VIP, NGLY1, GLP1R KLK7 326/4885KLK5 403/4885CTSS 273/4885
US-20210061860-A1 PEPTIDE-COMPOUND CYCLIZATION METHOD VIP, NGLY1, GLP1R KLK7 326/4885KLK5 403/4885CTSS 273/4885
US-20160311858-A1 PEPTIDE-COMPOUND CYCLIZATION METHOD VIP, NGLY1, GLP1R KLK7 326/4885KLK5 403/4885CTSS 273/4885
US-20150080549-A1 PEPTIDE-COMPOUND CYCLIZATION METHOD VIP, NGLY1, GLP1R KLK7 326/4885KLK5 403/4885CTSS 273/4885
US-12415835-B2 Peptide-compound cyclization method VIP, NGLY1, GLP1R KLK7 326/4885KLK5 403/4885CTSS 273/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.